Effient Approval Shows Mark Of FDA Controls

Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet